Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats.

Sustained and safe delivery of dopamine across the blood brain barrier (BBB) is a major hurdle for successful therapy in Parkinson's disease (PD), a neurodegenerative disorder. Therefore, in the present study we designed neurotransmitter dopamine-loaded PLGA nanoparticles (DA NPs) to deliver dopamine to the brain. These nanoparticles slowly and constantly released dopamine, showed reduced clearance of dopamine in plasma, reduced quinone adduct formation, and decreased dopamine autoxidation. DA NPs were internalized in dopaminergic SH-SY5Y cells and dopaminergic neurons in the substantia nigra and striatum, regions affected in PD. Treatment with DA NPs did not cause reduction in cell viability and morphological deterioration in SH-SY5Y, as compared to bulk dopamine-treated cells, which showed reduced viability. Herein, we report that these NPs were able to cross the BBB and capillary endothelium in the striatum and substantia nigra in a 6-hydroxydopamine (6-OHDA)-induced rat model of PD. Systemic intravenous administration of DA NPs caused significantly increased levels of dopamine and its metabolites and reduced dopamine-D2 receptor supersensitivity in the striatum of parkinsonian rats. Further, DA NPs significantly recovered neurobehavioral abnormalities in 6-OHDA-induced parkinsonian rats. Dopamine delivered through NPs did not cause additional generation of ROS, dopaminergic neuron degeneration, and ultrastructural changes in the striatum and substantia nigra as compared to 6-OHDA-lesioned rats. Interestingly, dopamine delivery through nanoformulation neither caused alterations in the heart rate and blood pressure nor showed any abrupt pathological change in the brain and other peripheral organs. These results suggest that NPs delivered dopamine into the brain, reduced dopamine autoxidation-mediated toxicity, and ultimately reversed neurochemical and neurobehavioral deficits in parkinsonian rats.

[1]  M. Rice,et al.  Immunocytochemical identification of proteins involved in dopamine release from the somatodendritic compartment of nigral dopaminergic neurons , 2009, Neuroscience.

[2]  A. Moustafa,et al.  Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease , 2014, Front. Aging Neurosci..

[3]  D. Green,et al.  Mitochondria and cell death: outer membrane permeabilization and beyond , 2010, Nature Reviews Molecular Cell Biology.

[4]  A. Björklund,et al.  Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. , 2005, Brain : a journal of neurology.

[5]  L. Bubacco,et al.  Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine , 2007, Journal of Biological Chemistry.

[6]  L. Denoroy,et al.  A rapid and sensitive method for the analysis of brain monoamine neurotransmitters using ultra-fast liquid chromatography coupled to electrochemical detection. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  K. Mohanakumar,et al.  Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism , 2007, Behavioural Brain Research.

[8]  L. Pei,et al.  Extracellular dopamine induces the oxidative toxicity of SH‐SY5Y cells , 2008, Synapse.

[9]  Zhenguo Liu,et al.  Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats , 2012, International journal of nanomedicine.

[10]  N. Roy,et al.  Enhanced survival and function of neural stem cells‐derived dopaminergic neurons under influence of olfactory ensheathing cells in parkinsonian rats , 2009, Journal of neurochemistry.

[11]  Seung U. Kim,et al.  Selective Susceptibility of Human Dopaminergic Neural Stem Cells to Dopamine-Induced Apoptosis , 2010, Experimental neurobiology.

[12]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[13]  M. Vacca,et al.  Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study. , 2011, Molecular pharmaceutics.

[14]  P. Mutlu,et al.  Synthesis of Doxorubicin loaded magnetic chitosan nanoparticles for pH responsive targeted drug delivery. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  N. Chandra,et al.  Mechanical stretch exacerbates the cell death in SH-SY5Y cells exposed to paraquat: mitochondrial dysfunction and oxidative stress. , 2014, Neurotoxicology.

[16]  A. Lang,et al.  Pharmacological treatment of Parkinson disease: a review. , 2014, JAMA.

[17]  Xinguo Jiang,et al.  Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. , 2011, International journal of pharmaceutics.

[18]  T. Golde.  The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease , 2009, Molecular Neurodegeneration.

[19]  V. B. Morris,et al.  Nanoparticle-mediated catalase delivery protects human neurons from oxidative stress , 2013, Cell Death and Disease.

[20]  T. Guilarte,et al.  Intrastriatal dopamine infusion reverses compensatory increases in D2-dopamine receptors in the 6-OHDA lesioned rat. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[21]  J. Doorn,et al.  Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity , 2012, Brain Research.

[22]  Alan C. Evans,et al.  Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Sun-Hee Kim,et al.  Activation of c-jun N-terminal kinase/stress-activated protein kinase and the decreased ratio of Bcl-2 to Bax are associated with the auto-oxidized dopamine-induced apoptosis in PC12 cells , 1998, Neuroscience Letters.

[24]  A. Galván,et al.  Intrapallidal dopamine restores motor deficits induced by 6-hydroxydopamine in the rat , 2009, Journal of Neural Transmission.

[25]  K. Gupta,et al.  Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model via canonical Wnt/β-catenin pathway. , 2014, ACS nano.

[26]  J. Siepmann,et al.  PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine. , 2013, International journal of pharmaceutics.

[27]  H. Kim,et al.  Intracerebral dialysis: direct evidence for the utility of 3-MT measurements as an index of dopamine release. , 1987, Life sciences.

[28]  W. D. de Jong,et al.  The kinetics of the tissue distribution of silver nanoparticles of different sizes. , 2010, Biomaterials.

[29]  N. Quinn,et al.  Upregulation of dopamine D2 receptors in dopaminergic drug‐naive patients with parkin gene mutations , 2006, Movement disorders : official journal of the Movement Disorder Society.

[30]  D. Grimes,et al.  Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material , 2004, Acta Neuropathologica.

[31]  Guohua Yu,et al.  Quinoprotein Adducts Accumulate in the Substantia Nigra of Aged Rats and Correlate with Dopamine-Induced Toxicity in SH-SY5Y Cells , 2011, Neurochemical Research.

[32]  T. Dalkara,et al.  Transport of a caspase inhibitor across the blood-brain barrier by chitosan nanoparticles. , 2012, Methods in enzymology.

[33]  M. Avila-Costa,et al.  Effect of Chronic L-Dopa or Melatonin Treatments after Dopamine Deafferentation in Rats: Dyskinesia, Motor Performance, and Cytological Analysis , 2012, ISRN neurology.

[34]  E. Souto,et al.  Surface modified PLGA nanoparticles for brain targeting of Bacoside-A. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  Tayyaba Hasan,et al.  Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. , 2009, Molecular pharmaceutics.

[36]  M. Asanuma,et al.  Astrocyte‐derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity , 2011, Glia.

[37]  A. Phillips,et al.  Transforming Growth Factor-β1 (TGF-β1)-stimulated Fibroblast to Myofibroblast Differentiation Is Mediated by Hyaluronan (HA)-facilitated Epidermal Growth Factor Receptor (EGFR) and CD44 Co-localization in Lipid Rafts* , 2013, The Journal of Biological Chemistry.

[38]  L. Bubacco,et al.  Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. , 2010, Biochimica et biophysica acta.

[39]  T. Sotnikova,et al.  Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. , 2006, CNS & neurological disorders drug targets.

[40]  P. Seth,et al.  Olfactory ensheathing cell transplantation restores functional deficits in rat model of Parkinson's disease: a cotransplantation approach with fetal ventral mesencephalic cells , 2004, Neurobiology of Disease.

[41]  J. Dalley,et al.  Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF , 2009, Proceedings of the National Academy of Sciences.

[42]  C. Waters,et al.  Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease , 2013, Expert review of neurotherapeutics.

[43]  M. Giovannelli,et al.  The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study , 2013, European Journal of Medical Research.

[44]  Guangjun Nie,et al.  Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. , 2011, Biomaterials.

[45]  A. Agrawal,et al.  Salsolinol induced apoptotic changes in neural stem cells: amelioration by neurotrophin support. , 2013, Neurotoxicology.

[46]  D. Kirik,et al.  Differential Dopamine Receptor Occupancy Underlies L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson's Disease , 2014, PloS one.

[47]  T. Unger,et al.  Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction , 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[48]  M. Hussein,et al.  Toxicity and Metabolism of Layered Double Hydroxide Intercalated with Levodopa in a Parkinson’s Disease Model , 2014, International journal of molecular sciences.

[49]  S. Pun,et al.  Neuron‐specific delivery of nucleic acids mediated by Tet1‐modified poly(ethylenimine) , 2007, The journal of gene medicine.

[50]  Diane J Burgess,et al.  Effect of acidic pH on PLGA microsphere degradation and release. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Haeshin Lee,et al.  Dopamine‐loaded poly(d,l‐lactic‐co‐glycolic acid) microspheres: New strategy for encapsulating small hydrophilic drugs with high efficiency , 2014, Biotechnology progress.

[52]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[53]  M. Hussein,et al.  Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes , 2015, Beilstein journal of nanotechnology.

[54]  D. Salat,et al.  Levodopa in the treatment of Parkinson's disease: current status and new developments. , 2013, Journal of Parkinson's disease.

[55]  L. Bubacco,et al.  Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. , 2007, The Journal of biological chemistry.

[56]  J. Pérez-Olea,et al.  Enhancement of Blood Pressure Response to Dopamine by Angiotensin II , 1981, Hypertension.

[57]  R. Morrison,et al.  p53 and mitochondrial function in neurons. , 2014, Biochimica et biophysica acta.

[58]  L. Bubacco,et al.  Human SOD2 Modification by Dopamine Quinones Affects Enzymatic Activity by Promoting Its Aggregation: Possible Implications for Parkinson’s Disease , 2012, PloS one.

[59]  K. Ohkubo,et al.  Radical scavenging reactivity of catecholamine neurotransmitters and the inhibition effect for DNA cleavage. , 2010, The journal of physical chemistry. B.

[60]  A. Letai,et al.  Control of mitochondrial apoptosis by the Bcl-2 family , 2009, Journal of Cell Science.

[61]  F. Zhou,et al.  Supersensitive presynaptic dopamine D2 receptor inhibition of the striatopallidal projection in nigrostriatal dopamine-deficient mice. , 2013, Journal of neurophysiology.

[62]  V. Kostic,et al.  Validation and cross-cultural adaptation of the Self-Assessment Disability Scale in patients with Parkinson’s disease in Serbia , 2013, Journal of the Neurological Sciences.

[63]  R. Chandra,et al.  Attenuation of arsenic neurotoxicity by curcumin in rats. , 2009, Toxicology and applied pharmacology.

[64]  M. Kuhar,et al.  The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[65]  R. Chaturvedi,et al.  Zuckerkandl's organ improves long-term survival and function of neural stem cell derived dopaminergic neurons in Parkinsonian rats , 2008, Experimental Neurology.

[66]  R. Chaturvedi,et al.  Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease , 2006, Neuroscience Letters.

[67]  M. Asanuma,et al.  Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. , 2004, Acta medica Okayama.

[68]  R. Barker,et al.  Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain , 2009, Cell cycle.

[69]  K. Seth,et al.  Neuroprotective potentials of neurotrophin rich olfactory ensheathing cell's conditioned media against 6OHDA-induced oxidative damage , 2014, Free radical research.

[70]  Jongheon Shin,et al.  Regulatory effects of costunolide on dopamine metabolism-associated genes inhibit dopamine-induced apoptosis in human dopaminergic SH-SY5Y cells , 2012, Neuroscience Letters.

[71]  S. Rasmussen,et al.  Visualization of Dopamine Transporter Trafficking in Live Neurons by Use of Fluorescent Cocaine Analogs , 2009, The Journal of Neuroscience.

[72]  M. Das,et al.  Association between children death and consumption of Cassia occidentalis seeds: clinical and experimental investigations. , 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[73]  I. G. Kondrasheva,et al.  Increasing the Efficiency of Parkinson's Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System , 2014, Experimental neurobiology.

[74]  Tomas Björklund,et al.  Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. , 2007, Current gene therapy.

[75]  Y. Kato,et al.  Effects of dopamine and L‐DOPA on survival of PC12 cells , 2000, Journal of neuroscience research.

[76]  K C Gupta,et al.  Imidazolyl-PEI modified nanoparticles for enhanced gene delivery. , 2007, International journal of pharmaceutics.

[77]  B. Sarmento,et al.  Assessing the physical-chemical properties and stability of dapivirine-loaded polymeric nanoparticles. , 2013, International journal of pharmaceutics.

[78]  M. Asanuma,et al.  Striatal Astrocytes Act as a Reservoir for L-DOPA , 2014, PloS one.

[79]  S. Roy,et al.  Surface‐functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[80]  Giuseppe Trapani,et al.  Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. , 2011, International journal of pharmaceutics.

[81]  Ikuko Miyazaki,et al.  Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease , 2009, Neurotoxicity Research.

[82]  L. P. van der Heide,et al.  The BCL2 code to dopaminergic development and Parkinson's disease. , 2013, Trends in molecular medicine.

[83]  Patrick Couvreur,et al.  A Nanomedicine Transports a Peptide Caspase-3 Inhibitor across the Blood–Brain Barrier and Provides Neuroprotection , 2009, The Journal of Neuroscience.

[84]  Jose Vicente Lafuente,et al.  Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease , 2014, International journal of nanomedicine.

[85]  K. Gupta,et al.  Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism. , 2013, Free radical biology & medicine.

[86]  V. Pickel,et al.  Region‐specific targeting of dopamine D2‐receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions , 2002, Synapse.

[87]  P. Schotte,et al.  Ultrastructural localization of cytochrome c in apoptosis demonstrates mitochondrial heterogeneity , 2000, Cell Death and Differentiation.

[88]  Weien Yuan,et al.  Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats , 2011, Neuroscience Letters.

[89]  Youxin Li,et al.  Preparation of Rotigotine-Loaded Microspheres and Their Combination Use with L-DOPA to Modify Dyskinesias in 6-OHDA-Lesioned Rats , 2012, Pharmaceutical Research.

[90]  T. Dalkara,et al.  An aquaporin 4 antisense oligonucleotide loaded, brain targeted nanoparticulate system design. , 2014, Die Pharmazie.

[91]  S. Lazzari,et al.  Colloidal stability of polymeric nanoparticles in biological fluids , 2012, Journal of Nanoparticle Research.

[92]  P. Santiago-Jacinto,et al.  Tio2-dopamine complex implanted unilaterally in the caudate nucleus improves motor activity and behavior function of rats with induced hemiparkinsonism. , 2011, Proceedings of the Western Pharmacology Society.

[93]  J. Siepmann,et al.  PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[94]  Charles Duyckaerts,et al.  Dopamine depletion impairs precursor cell proliferation in Parkinson disease , 2004, Nature Neuroscience.